Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases
Identification
- Public canonical key
- radar:r-84d1a9d9a6f492ef636802dfa042369b
- Authors
- Ning Huang · Liming Wang · Hongming Deng · Chenyang Nan · Zhenbang Ye · Changchun Zhou · Jiajun Zhang · Ruoyu Zhang · Ke Xu · Jianxiong Wu · Rui Liu · Mei Liu
- Reported year
- 2026
- Reported language
- en
- Source type
- article
- First detected
- 2026-11-14T02:13:03.394657+00:00
- Last metadata observation
- 2026-11-14T02:13:03.394657+00:00
- Last HTTP verification
- Not checked
Institutions reported by the source
Chinese Academy of Medical Sciences & Peking Union Medical College · Cancer Hospital of Chinese Academy of Medical Sciences · State Key Laboratory of Molecular Oncology · Shandong Tumor Hospital · Shandong First Medical University · Tianjin Medical University Cancer Institute and Hospital · Tianjin Medical University
Reported affiliation countries
CN
Documentary abstract — original language
Abstract Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, and liver metastases stands as a leading contributor to its high mortality rate in advanced stages. Regorafenib plus anti-PD-1 is a new therapeutic option for patients with colorectal cancer liver metastases (CRCLM). However, a considerable number of patients have not benefited from it. In this study, KRAS mutation was identified associated with resistance to regorafenib plus anti-PD-1 in CRCLM. Dihydroartemisinin (DHA), a clinically approved anti-malaria agent, was verified to selectively downregulate KRAS G12D mutant with no discernible influences on wild-type KRAS, which is consistent with the higher sensitivity of KRAS -mutant CRC cells and organoids to DHA treatment. In preclinical KRAS G12D CRCLM models, DHA substantially potentiated the therapeutic efficacy of regorafenib plus anti-PD-1 by remodeling the tumor immune microenvironment, including enhancing the cytotoxicity of CD8 + effector T cells and promoting pro-inflammatory macrophage polarization. Mechanically, DHA could restore interferon response that was impaired by oncogenic KRAS mutations, and inhibit ERBB signaling activation induced by regorafenib. Collectively, these findings support DHA as a potential adjunct to regorafenib plus anti-PD-1 for KRAS G12D CRCLM and suggest a therapeutic strategy with translational potential for KRAS -driven malignancies.
Identifiers
- OPENALEX
- https://openalex.org/W7167412604
- DOI
- 10.1038/s41419-026-09042-z
- PMID
- https://pubmed.ncbi.nlm.nih.gov/42402611
- PMCID
- https://www.ncbi.nlm.nih.gov/pmc/articles/13612556
Documentary context
- Documentary family
- article
- Source-reported types
- article
- Publishers
- Springer Nature
Entity mentions are not evidence of legal recognition. Jurisdiction studied is separate from author affiliation country.
Sources
OpenAlex · Record 1
Cite this reference
Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. 2026. https://doi.org/10.1038/s41419-026-09042-z
JSON · CSL-JSON · BibTeX · RIS · CSV · JSON-LD ·
APA, Chicago, ISO 690: bibliographic formats using available fields. OSCOLA / Bluebook: structured data only; full legal citation compliance is not claimed without verification of required elements.
- APA
- Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. (2026). Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. https://doi.org/10.1038/s41419-026-09042-z
- Chicago
- Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. 2026. https://doi.org/10.1038/s41419-026-09042-z
- ISO 690
- Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. 2026. https://doi.org/10.1038/s41419-026-09042-z
Warning: Undefined array key "last_link_verified" in /home/clients/e27d81e12f04d2bfd747aa264540ac56/sites/_UDTR_APP/legal_library_reference.php on line 31
UDTR Global Rights of Nature Legal Library. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. Documentary record: https://www.declarationuniverselledesdroitsdelarbre.org/global-rights-of-nature-radar/reference/r-84d1a9d9a6f492ef636802dfa042369b/ · Last HTTP verification: not performed
Research dossiers and documentary relations
Source roles
Bibliographic / original publication source · https://doi.org/10.1038/s41419-026-09042-z
An authority link alone does not verify a legal claim. Abstracts and full texts remain subject to their source terms.
Documentary status
Relevance pending
Library
This identity is not yet included in the Legal Library.